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Uptake of genetic testing by the children of Lynch
syndrome variant carriers across three generations
Toni T Seppälä*,1, Kirsi Pylvänäinen2 and Jukka-Pekka Mecklin2,3
Many Lynch syndrome (LS) carriers remain unidentified, thus missing early cancer detection and prevention opportunities.
Tested probands should inform their relatives about cancer risk and options for genetic counselling and predictive gene testing,
but many fail to undergo testing. To assess predictive testing uptake and demographic factors influencing this decision in LS
families, a cross-sectional registry-based cohort study utilizing the Finnish Lynch syndrome registry was undertaken. Tested LS
variant probands (1184) had 2068 children divided among three generations: 660 parents and 1324 children (first), 445 and
667 (second), and 79 and 77 (third). Of children aged 418 years, 801 (67.4%), 146 (43.2%), and 5 (23.8%), respectively,
were genetically tested. Together, 539 first-generation LS variant carriers had 2068 children and grandchildren (3.84 per
carrier). Of the 1548 (2.87 per carrier) eligible children, 952 (61.5%) were tested (1.77 per carrier). In multivariate models,
age (OR 1.08 per year; 95% CI 1.06–1.10), family gene (OR 2.83; 1.75–4.57 for MLH1 and 2.59; 1.47–4.56 for MSH2
compared with MSH6), one or more tested siblings (OR 6.60; 4.82–9.03), no siblings (OR 4.63; 2.64–8.10), and parent under
endoscopic surveillance (OR 5.22; 2.41–11.31) were independent predictors of having genetic testing. Examples of parental
adherence to regular surveillance and genetically tested siblings strongly influenced children at 50% risk of LS to undergo
predictive gene testing. High numbers of untested, adult at-risk individuals exist even among well-established cohorts of known
LS families with good adherence to endoscopic surveillance.
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INTRODUCTION
Lynch syndrome (LS) predisposes to high lifetime risk of malignancies,
including colorectal (CRC) and endometrial cancers, and tumours at
several other extracolonic sites, such as gastric, ovarian, hepatobiliary,
urinary tract, small bowel, central nervous system, pancreas, prostate,
and breast cancer. The cumulative prospective risks for any cancer in
patients with LS at the age of 70 years vary according to the mismatch
repair (MMR) gene affected: MLH1 75%, MSH2 79%, MSH6 53%,
and PMS2 37%, although the overall 10-year survival after any first
cancer is generally good, at 87%.1 However, the majority of LS variant
carriers are unaware of their condition and the underlying cancer risk2
despite the recommendations for universal immunohistochemistry
screening of all new CRC cases.3–6 Unfortunately, some guidelines,
such as those of the National Comprehensive Cancer Network,7
recommend genetic testing of LS only for individuals who meet
clinical criteria (Amsterdam II or the revised Bethesda guidelines) that
are known to miss a large proportion of LS carriers.8 As a
consequence, recommendations for universal tumour screening are
not widely followed that decreases the numbers of LS diagnoses. In
addition, the cost-effectiveness of universal LS screening of CRC with
immunohistochemistry and BRAF mutation status depends on the
predictive testing (PT) uptake rate among relatives.9
In particular, subjects without personal cancer history but belonging
to LS families with an ascertained gene variant are able to obtain risk
assessment and genetic counselling via national LS registries and
health-care professionals. The clinical management of first-, second-,
and third-degree relatives of LS probands begins with the provision of
information regarding the benefits of family member genetic counsel-
ling followed by PT.3 PT is available to all at-risk relatives in families
with known MMR gene variants affecting function.8 Overall, improved
diagnostics of LS offers several advantages. First, increased surveillance,
including frequent colonoscopy at a 1–3-year interval, is offered to
those with a proven gene variant.3,6,10,11 Surveillance colonoscopy of
known LS carriers improves the detection rate of CRC and greatly
improves survival compared with those not under surveillance.12
Second, new additional treatment and prevention modalities for
MMR-deficient cancers such as checkpoint inhibitors, vaccines, and
chemoprevention are under development, which may improve the
prognosis of LS. Third, tested non-carriers are released from the
requirement for burdensome surveillance, because their risk is at
the general population level.
However, the uptake of genetic counselling and PT is known to be
poor among first-degree relatives (FDRs) of identified probands. Only
30–52% of LS proband relatives receive counselling although the
frequency of genetic testing among those counselled is 95%.13–15 The
major problem is that the parents’ or relatives’ disclosure (or non-
disclosure) of carrier status does not effectively lead to genetic
counselling. On average, only three unaffected relatives are tested
per one identified carrier.3,13–15 Together, these observations indicate
that most LS carriers are not identified and thus the potential for
cancer prevention is missed, which is unsatisfactory in the era of
precision medicine.16
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The Finnish LS registry (LSRFi) has recorded patients with LS
since the 1980s, prior to the availability of PT. In many of the
families, three generations of carriers have already been tested.
However, there are no reports regarding the potential change in
counselling and PT uptake from one generation to the next in
known LS families. The objective of this analysis was to
identify factors in the LS families that predict the decision to
undergo PT.
Table 1 Clinical characteristics of the MMR variant carriers and their offspring
First generation Second generation Third generation All
Parents
MMR variant carriers, n 660 445 79 1184
Sex
Female (%) 352 (53.3) 219 (49.2) 32 (40.5) 603 (50.9)
Male (%) 308 (46.7) 226 (50.8) 47 (59.5) 581 (49.1)
Vital status
Deceased (%) 158 (23.9) 26 (5.8) 1 (1.3) 185 (15.6)
Number from cancer 99 20 0 119
Living (%) 502 (76.1) 419 (94.2) 78 (98.7) 999 (84.4)
Age (parents alive)
Mean (SD) 60.4 (12.4) 42.6 (11.6) 31.8 (8.1) 50.7 (15.5)
Cancer status
Cancer (%) 449 (68.0) 133 (29.9) 5 (6.3) 587 (49.6)
No cancer (%) 211 (32.0) 312 (70.1) 74 (93.7) 597 (50.4)
Number with children
Has children (%) 539 (81.7) 298 (67.0) 36 (45.6) 873 (73.7)
No children (%) 121 (18.3) 147 (33.0) 43 (54.4) 311 (26.3)
Number of children
Mean (SD) 1.9 (1.4) 1.5 (1.4) 1.0 (1.3) 1.7 (1.4)
Range 0–10 0–9 0–4 0–10
Under surveillance (of those alive)
Yes (%) 465 (93.8) 390 (94.9) 73 (96.1) 928 (94.4)
No (%) 31 (6.3) 21 (5.1) 3 (3.9) 55 (5.6)
Missing 6 8 2 16
Gene affected
MLH1 (%) 500 (75.8) 340 (76.4) 66 (83.5) 906 (76.5)
MSH2 (%) 109 (16.5) 79 (17.8) 8 (10.1) 196 (16.6)
MSH6 (%) 51 (7.7) 26 (5.8) 5 (6.3) 82 (6.9)
Children
Number of children 1324 667 77 2068
Sexa
Female (%) 641 (48.4) 320 (48.1) 40 (51.9) 1061 (51.3)
Male (%) 679 (51.3) 345 (51.7) 37 (48.1) 1001 (48.4)
Missing 4 (0.3) 2 (0.3) 0 6 (0.3)
Vital status
Deceased (%) 36 (2.7) 8 (1.2) 0 44 (2.1)
Living (%) 1288 (97.3) 659 (98.8) 77 (100.0) 2024 (97.9)
Age (of those alive)
Mean (SD) 40.4 (15.2) 20.0 (12.0) 12.8 (7.6) 32.7 (17.4)
418 years (%) 1189 (92.3) 338 (51.3) 21 (27.3) 1548 (76.4)
o18 years (%) 99 (7.7) 321 (48.7) 56 (72.7) 476 (23.6)
Tested (of those alive)
Tested aged 418 years (%) 801 (62.2) 146 (21.9) 5 (6.5) 952 (46.0)
Not tested aged 418 years (%) 388 (30.1) 192 (28.8) 16 (20.8) 596 (28.9)
Not tested aged o18 years (%) 99 (7.7) 321 (48.1) 56 (72.7) 476 (22.9)
Parent gene affected
MLH1 (%) 1019 (77.0) 517 (77.5) 68 (88.3) 1604 (77.6)
MSH2 (%) 203 (15.3) 112 (16.8) 4 (5.2) 319 (15.4)
MSH6 (%) 102 (7.7) 38 (5.7) 5 (6.5) 145 (7.0)
Number of siblings
Mean (SD) 2.1 (1.6) 1.8 (1.3) 1.6 (1.0) 2.0 (1.5)
Range 0–9 0–8 0–3 0–9
aSex was missing for six subjects.
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METHODS
Data collection
The study subjects consisted of members of LS families in the LSRFi, which
includes demographic, genetic, and clinical information on patients and carriers
of identified LS families. The registry works as a national research database of
patients and high-risk family members. The families have been included in the
registry based on clustered LS cancers, and after verification of the proband
germline variant, the pedigrees of the families have been created. The
genealogical survey was based on the Finnish Population Register, which has
enabled the complete registration of all offspring of the LS variant carriers.
A written informed consent to include them in LSRFi was obtained from each
tested individual. The administration of the Central Finland health-care district
approved this registry study, which did not require any direct contact with
individuals in the registry.
At the time of analysis (October 2015), the LSRFi consisted of 270 families
with 1184 tested LS variant carriers that had a total of 2068 known children.
The database included all at-risk relatives who had not opted for testing but
carried a risk of harbouring an LS variant as direct offspring.17 The original
cohort of 660 first-generation LS carriers, who were not children of any other
registered LS probands themselves, was analysed with their offspring forming
the second and third generations of tested and non-tested subjects. Age, sex,
family structure, family history of cancer, cause of death, and adherence to
colonoscopy surveillance in each generation was recorded for this report.
Genetic testing
Relatives of known LS probands were eligible for genetic testing after 18 years of
age. The children of LS carriers were mainly offered testing (i) when the subject
contacted the LS registry genetic counsellor upon encouragement by a relative
(known proband); (ii) when the subject attended genetic counselling based on
family cancer history; or (iii) in case of LS cancer of their own. In 2003, 286
subjects of the registry were sent a letter as part of a direct-contact approach
(DCA) study resulting in 112 subjects being tested, of which 32 were tested
positive.18 In 1995–1998, 446 subjects were contacted by their family member
with a letter from the LS registry as a part of a family-mediated approach
(FMA) study, resulting in 334 subjects being tested, of which 99 were tested
positive.19 Subjects of these two contact studies represented carriers and non-
carriers of the first and second generation of this study. Outside of these two
studies, no direct contact by the registry personnel was established.
Statistical analysis
A chi-square test was used for categorical variables and an independent sample
t-test was used for continuous normally distributed variables when determining
the statistical significance between tested and untested subjects. One-way
ANOVA was used for multiple comparisons of continuous variables. Logistic
regression analysis was used as a multivariate model for continuous and
categorical variables. Variables with Po0.2 in univariate analysis were included
in the model. Otherwise, Po0.05 was considered as a limit for statistical
significance. All statistical tests were two sided. Some continuous variables such
as number of siblings were categorized to provide more readable results. To fit
most subjects to the multivariate model, the age of a deceased parent was
categorized as ‘dead’ and compared as a single age group. Statistical analyses
were conducted using SPSS for Mac 23.0.0.0 (IBM Corp., Armonk, NY, USA).
RESULTS
In total, 1184 tested LS probands had 2068 children of which 2024
(97.9%) were alive at the time of the study. Of those aged 418 years
(n= 1548, 76.4%), 952 (61.5%) had undergone PT and 596 (38.5%)
had not. Those aged o18 years (n= 476, 23.6%) were not tested.
The data were divided into generations of LS carriers and their
offspring and are presented in Table 1 together with data of the whole
cohort. The first generation was formed by 660 probands, of which
539 (81.7%) had 1324 children (mean 2.5 children), of which 1288
(97.3%) were alive. Of those, 1189 (92.3%) were aged 418 years and
eligible for PT. Out of the 1189, 801 (67.4%) underwent PT with 445
(55.6%) subjects testing positive for a germ line variant of an MMR
gene affecting function, forming the second generation of LS variant
carriers.
In the second generation, out of the 445 carriers, 298 (67.0%) had
667 children (mean 2.2 per carrier with children), of which 659
(98.8%) were alive at the time of the study. Of the living children, 338
(51.3%) were aged 418 years and eligible for PT. Among those, 146
(43.3%) underwent testing, of which 79 (54.1%) were positive for
germline LS gene variant, thus forming the third generation of carriers.
Figure 1 Flowcharts of (a) first generation, (b) second generation, and
(c) third generation.
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In the third generation, the mean age of variant carriers was 31.8
years, of whom only 36 (45.6%) had children. Of the 77 total children,
all were alive and 21 (27.3%) were eligible for PT. Five (20.8%)
subjects at 50% risk had already opted for PT, with one testing positive
for germ line variant, starting the fourth generation of tested carriers.
Taken together, 539 variant carriers of the first generation had 2068
children and grandchildren (3.84 per carrier), of which 1548 (2.87 per
carrier, 76.5%) were alive and eligible for PT, with 952 (61.5%) having
been tested (1.77 per carrier). Flowcharts of the formation of each
generation are presented in Figure 1a–c. The numbers of children of
each generation of carriers are presented in Figure 2.
The offspring of the first generation (40.4 years) were generally
older than the children of the second (20.0 years) and the third (12.8
years) generation of LS variant carriers. Our analysis was focussed on
those eligible for testing, that is, 418 years of age, and on the
demographic covariates of their decision to undergo PT.
Factors influencing the uptake of genetic testing
In three generations, 1548 subjects were eligible for PT. Those having
had PT were older than those who had not undergone PT (44.8 vs 31.4
years, Po0.001) although they did not differ statistically by sex. Of
those who were not tested, 57.7% were aged o30 years, whereas
88.6% of the tested were aged 430 years. Children of MSH6 variant
carriers were less likely to be tested compared with those ofMLH1 and
MSH2 variant carriers. In addition, having a female parent as a carrier
was statistically significantly associated with offspring being tested.
Cancer or death of a carrier parent (but not cancer death) represented
the strongest predictors of PT. In addition, higher age of a parent and
one or more siblings chosen to take PT were associated with the
probability of being tested. Comparison of adults who underwent and
who did not undergo genetic testing in each generation are presented
in Table 2.
Of the 55 tested carriers not under regular surveillance at the time
of the analysis, 23 were living abroad. Of the remaining 32, 19 were
first-generation, 12 second-generation and 1 third-generation carriers.
Only 26 actually declined surveillance, but 6 repeatedly did not attend
the scheduled appointment.
Multivariate analysis
Variables with Po0.2 in univariate analysis included the age of the
subject age (continuous), affected gene or sex of the parent,
categorized number of siblings, whether a sibling was tested, and
categorized age, cancer status, and endoscopic surveillance of the
parent. For those whose parent was deceased, endoscopic surveillance
was categorized as ‘yes’ and parent age was categorized as ‘dead’. Out
of the 1548 subjects, a total of 1525 were included in the logistic
regression model (Table 3).
From the covariates tested in the multivariate model, age, gene,
number of siblings, siblings having been tested, and prior or ongoing
endoscopic surveillance of the parent were independent factors of the
decision of having had PT. Parent sex and prior cancer of a parent
were statistically non-significant in the logistic regression model. Being
an only child (OR 4.63), a sibling to a tested carrier (OR 6.60) or
having a parent under endoscopic surveillance (OR 5.22) represented
the strongest predictors of having opted for PT. To avoid bias that may
have been derived from a high number of 18–25-year-old subjects
who may still be in the process of considering having PT, we
conducted the multivariate model on those aged 425 years. The
same variables were independent predictors of PT, and in addition,
prior cancer in a parent was identified as a statistically significant
covariate as well (OR 1.40; 1.01–1.95).
DISCUSSION
In the current study, 67.4% of disclosure-aged children of the first
generation, 43.2% of the second and 23.8% of the third had chosen to
undergo PT. The decrease of uptake rate by generation may be
explained by the age distribution of the offspring: even though the
limit of 18 years of age enables the possibility to undergo PT, the
average age of getting tested was 32.5 years. However, as the PT
became available in the mid-1990’s, many of the first-generation
children underwent testing when they were older than the tested
individuals among the second- and third-generation children. It is
reasonable that older subjects have become more adjusted over time to
the idea of possibly having LS and also simply had more time to get
tested than the younger individuals. It also appears possible that at-risk
persons currently become tested at younger age when testing is
available in their youth; conversely, the uptake of PT may decrease
as the prognosis of common LS-related cancers has improved.
It is known that the disclosure of personal test results to children
among LS carriers is generally good. Nearly 90% of tested individuals
with children informed their offspring of the test result20; however, the
resulting uptake of children to undergo PT was not reported in the
study, as this factor is infrequently documented and is therefore
generally not known. Instead, the majority of previous studies have
addressed the proportion of FDRs at risk to undergo genetic testing,
including siblings, parents, and children.
For example, 90% of FDRs in a Finnish FMA study in 2000
consented to the study, 78% consented to genetic counselling, and
75% (334/446) underwent PT.19 After completing the FMA study in
2003, a DCA study was carried out, wherein 51% of relatives
consented to the study, 40% (113/286) consented to counselling,
and 39% (112/286) underwent PT.18 The lower figures of participation
were obviously a consequence of the fact that the non-consented
relatives were partly the same in both studies. In the latter study, the
low proportion of LS variant-positive individuals (32/112, 28%)
among the tested subjects is also reflective of inclusion of the cohort
of relatives at 25% risk.18 Both previous interventions may have
increased PT uptake rate at the time.
Figure 2 Number of children of carriers in each generation grouped by age.
The separated portion of each bar represents the percentage tested within
the group.
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Furthermore, in a recent study, 56% (329/591) of FDRs of LS
variant carriers had undergone PT.21 Similarly, in a Dutch study by
Ramsoekh et al.,22 52% (330/640) of FDRs underwent PT, with 51%
(56/111) of FDRs choosing to undergo genetic testing after education
and counselling in another study.23 Conversely, two earlier studies
reported 43%24 and 60%25 uptake percentage, whereas in a large
multicentre study of MSH6 variant families, only 17% (525/3104) of
the relatives were tested, although the degree of the relatives was not
reported.26 In a South-African study, 63% of the tested probands
informed their children of the hereditary cancer risk and 73.6%
(64/87) of the eligible children underwent PT, which was lower than
the proportion of siblings tested (97%).27 In a systematic review, eight
eligible studies including FDRs of LS variant carriers were combined to
assess uptake to genetic testing. Less than 52% received genetic testing
and on average 3.6 relatives per proband were tested.15 Furthermore,
an original evidence review was undertaken by Palomaki et al.14 to
provide background data for an Evaluation of Genomic Applications
in Practice and Prevention Working Group recommendation. There
was adequate evidence to document the uptake of counselling among
1886 FDRs who were contacted (52%) and subsequently targeted for
PT (95% of those counselled). If the study of Aktan-Collan et al.19 was
not included, the uptake for counselling would have been 46% and the
uptake for testing 95%.14
As demonstrated by these reports, the results of PT uptake have
been variable, and the uptake of PT by offspring has been infrequently
reported separately. Most often, the reported uptake rates have been
results of a questionnaire or other intervention. Our results do not
contradict earlier studies but rather provide a different viewpoint from
one generation of carriers to the next over the natural course of family
history. The strength of the current study is that it was not an
interventional study based on a questionnaire but a registry observa-
tion of results reflecting continued work carried out since the 1980s
using primarily FMA (plus one limited DCI study). The difference
from earlier reports is that we did not study PT uptake of all FDRs but
only the children and grandchildren of the original carriers. This
yielded a result of only 1.8 tested children/grandchildren per original
first-generation carrier, keeping in mind that some of these families
were related to each other.
Death of a parent and prior cancer history in the family have been
considered as warning examples for offspring to become tested in order
Table 3 Logistic regression analysis of covariates that were statistically significant in the univariate analysis
Children aged 418 years Children aged 425 years
Genetic testing as end variable Genetic testing as end variable
n=1525 n=1279
Covariates OR (95% CI) P OR (95% CI) P
Age per year 1.08 (1.06–1.10) o0.001 1.05 (1.03–1.07) o0.001
Parent gene affected
MSH6 1.00 (reference category) 1.00 (reference category)
MSH2 2.59 (1.47–4.56) 0.001 2.37 (1.32–4.25) 0.004
MLH1 2.83 (1.75–4.57) o0.001 2.77 (1.70–4.54) o0.001
Parent sex
Female 1.00 (reference category) 1.00 (reference category)
Male 1.30 (0.99–1.70) 0.064 1.34 (0.99–1.81) 0.051
Number of siblings
≥3 1.00 (reference category) 1.00 (reference category)
1–2 1.51 (1.08–2.10) 0.015 1.43 (0.99–2.03) 0.051
None 4.63 (2.64–8.10) o0.001 4.86 (2.63–10.61) o0.001
Siblings tested
None 1.00 (reference category) 1.00 (reference category)
≥1 6.60 (4.82–9.03) o0.001 7.00 (4.99–9.82) o0.001
Parent age
24–50 years 1.00 (reference category) 1.00 (reference category)
50–70 years 2.01 (1.21–3.33) 0.007 1.24 (0.61–2.50) 0.557
70–100 years 1.96 (0.92–4.18) 0.081 1.55 (0.62–3.83) 0.340
Dead 1.74 (0.89–3.39) 0.104 1.28 (0.54–2.99) 0.577
Parent under endoscopic surveillance
No 1.00 (reference category) 1.00 (reference category)
Yesa 5.22 (2.41–11.31) o0.001 4.90 (2.27–10.61) o0.001
Parent had cancer
No 1.00 (reference category) 1.00 (reference category)
Yes 1.34 (0.99–1.81) 0.055 1.40 (1.01–1.95) 0.043
aIf deceased, the parent was categorized as ‘yes’ for endoscopic surveillance.
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to prevent and detect upcoming cancers. Our study corroborated the
former assumption, even though the results were inconsistent in
multivariate analysis. The finding that having an MSH6 carrier as a
parent was associated with a lower probability of PT may be explained
by the same phenomenon: recent studies indicate that MSH6 carriers
have a slightly lower risk of cancer, especially at a young age, than
MLH1 and MSH2 carriers,1 which may modify the behaviour for
testing uptake in the family. Surveillance may also begin later in life, and
be less strict than for other genes, although this is not recommended in
Finland. In addition, our analysis identified new possible factors that
may influence the PT uptake. Being an only child was a strong positive
predictor to become tested, as was having a tested sibling. Belonging to
a family where some of the children have been tested is an indicator of
full disclosure of the variant in the family, which increases the
probability of PT for all siblings. A parent being under endoscopic
surveillance is an indicator of adherence to a health-care system that
enables a continuing discussion between the carrier and an endoscopist
about the disclosure and testing situation of the offspring. Conversely,
non-adherence to a surveillance programme, which is quite rare, is an
indicator that the family may not even know about the parental
function-affecting variant, which may increase the probability of the
offspring not being tested. Male carriers appeared to perform worse
with regards to their children becoming tested, although the effect of
sex did not reach significance in the multivariate model (P= 0.051).
To our knowledge, this is the first report to analyse the uptake of PT
by direct offspring across three generations of LS families. The
apparent strengths of the study are the high number of subjects, exact
family structures, the status of LSRFi as the only registry provider, and
limiting this analysis only to genetically tested probands. There were
also some limitations to address. Parenthood has been identified to
associate with genetic testing uptake in a previous study22; however,
we did not obtain the information on the number of children of those
who did not undergo PT or tested negative. We also did not have
access to educational background information, precluding character-
ization of this factor.24 Although LSRFi receives information from all
health-care providers in the country, it is possible that some
individuals may have undergone PT but refused to inform the registry.
However, carriers and at-risk individuals generally respond well to
information requests by LSRFi and usually do not decline, which is
also reflected by the 97.8% adherence rate to endoscopic
surveillance.17,28,29 Therefore, we consider that there is low risk of
compromised data quality.
Considerable effort has been put into recognizing new LS families
through tumour testing but much less has been applied to discussing
the importance of counselling, testing, and surveillance of at-risk
FDRs. In comparison, the number of PTs for BRCA1/2 is constantly
increasing, whereas that for LS it is not, probably owing to poor
uptake of relatives at risk. In both predisposing syndromes, approxi-
mately a third of eligible relatives have been reported to undergo PT
but the worse overall performance of PT in LS is believed to reflect
lower level of information of patients and relatives.13 Unfortunately,
the cost-effectiveness of universal tumour screening strategies are
based on the successful PT uptake of high-risk relatives of individuals
identified.30 High numbers of remaining untested adult individuals
among LS families, even in a well-established nationally operated
registry, therefore represent a clinical challenge for the endoscopists
who meet with the tested carriers on a regular basis. A direct approach
to untested at-risk individuals and the development of new technol-
ogies should be considered within the limits of legislation and ethics to
improve the uptake of genetic testing in LS. Towards this goal, we have
launched a new DCA study to contact approximately 540 untested
persons at risk to improve our testing uptake.
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